Valuation : AbbVie Inc.

Market Cap 460B 396B 371B 340B 634B 43,467B 639B 4,392B 1,710B 22,213B 1,727B 1,689B 71,541B P/E 2026 *
33.2x
P/E 2027 * 24.6x
Enterprise Value 520B 448B 420B 384B 717B 49,185B 723B 4,970B 1,935B 25,136B 1,954B 1,911B 80,953B EV / Sales 2026 *
7.7x
EV / Sales 2027 * 6.96x
Free-Float
95.71%
Yield 2026 *
2.64%
Yield 2027 * 2.77%
09-03 AbbVie Announces Positive Topline Results From The Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma CI
09-03 AbbVie Inc. completed the acquisition of Apogee Therapeutics, Inc. from Fairmount Healthcare Fund II L.P managed by Fairmount Funds Management LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P managed by Venrock Management, LLC and other shareholders. CI
09-03 AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints MT
09-03 AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study DJ
09-03 AbbVie's blood cancer therapy lowers disease progression, death risk in trial RE
09-03 AbbVie's blood cancer drug meets late-stage trial goals RE
09-03 AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics MT
09-01 Global pharma companies that have publicly announced Trump drug pricing agreements RE
09-01 AbbVie Inc Receives Determination From Food And Drug Administration Regarding NAMENDA (Memantine Hydrochloride) Tablets 5 Mg And 10 Mg CI
08-27 AbbVie Seeks EU Approval for Subcutaneous Skyrizi Induction in Crohn's Disease MT
08-27 AbbVie Seeks European Regulatory Nod to Use Skyrizi as Subcutaneous Induction for Crohn's Disease Treatment MT
08-27 AbbVie Submits Regulatory Application To EMA For SKYRIZI (Risankizumab) Subcutaneous Induction For Adults With Moderately To Severely Active Crohn's Disease CI
08-26 Gubra Flags $50 Million Milestone Payment as AbbVie Begins Phase 2 Study of Obesity Drug MT
1 day-0.58%
1 week+0.80%
Current month+1.48%
1 month+6.16%
3 months+19.84%
6 months+11.27%
Current year+13.88%
1 week 252.33
Extreme 252.33
264.25
1 month 241.2
Extreme 241.2
266.96
Current year 190.75
Extreme 190.75
267.47
1 year 190.75
Extreme 190.75
267.47
3 years 135.85
Extreme 135.85
267.47
5 years 105.56
Extreme 105.56
267.47
10 years 55.06
Extreme 55.0623
267.47
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
8/14/26 A Exercice

Executive/Senior Manager

98,130 0.0056%
6/30/26 A Free

Director

62 0.0000%
6/30/26 A Free

Director

134 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.58%+0.80%+22.82%+75.58% 460B
-0.04%-1.40%+57.16%+108.15% 1,034B
+1.17%+4.76%+56.42%+73.50% 671B
-0.43%-1.20%+28.55%+37.55% 353B
-1.09%+4.95%+24.96%+45.86% 309B
+0.17%+1.65%-0.16%+13.83% 255B
+0.29%+1.63%+56.46%+73.00% 240B
-0.52%+1.37%-16.91%-54.30% 207B
+1.08%+1.59%+33.83%+97.29% 188B
-0.72%+2.82%+16.22%-19.48% 164B
Average -0.40%+1.43%+27.94%+45.10% 388.1B
Weighted average by Cap. -0.46%+1.12%+37.17%+63.93%

Financials

2026 *2027 *
Net sales 67.58B 58.15B 54.57B 49.93B 93.18B 6,389B 93.92B 646B 251B 3,265B 254B 248B 10,515B 73.52B 63.26B 59.36B 54.31B 101B 6,950B 102B 702B 273B 3,552B 276B 270B 11,439B
Net income 13.86B 11.93B 11.19B 10.24B 19.11B 1,310B 19.26B 132B 51.56B 670B 52.05B 50.92B 2,157B 18.91B 16.27B 15.27B 13.97B 26.08B 1,788B 26.28B 181B 70.35B 914B 71.03B 69.48B 2,943B
Net Debt 60.49B 52.05B 48.84B 44.69B 83.4B 5,718B 84.06B 578B 225B 2,922B 227B 222B 9,411B 51.66B 44.45B 41.71B 38.16B 71.23B 4,884B 71.79B 493B 192B 2,496B 194B 190B 8,038B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
03/09/26 $260.21 -0.58% 2,878,739
02/09/26 $261.72 +0.67% 4,225,524
01/09/26 $259.99 +1.39% 3,866,739
31/08/26 $256.42 +0.37% 4,315,487
28/08/26 $255.48 -1.03% 3,224,862
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
260.21USD
Average target price
276.59USD
Spread / Average Target
+6.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock